About BridgeBio Pharma, Inc.
https://www.bridgebio.comBridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development.
CEO
Neil Kumar
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 175
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 15
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:16.83M
Value:$1.31B
VIKING GLOBAL INVESTORS LP
Shares:15.98M
Value:$1.24B
BLACKROCK, INC.
Shares:14.41M
Value:$1.12B
Summary
Showing Top 3 of 442
About BridgeBio Pharma, Inc.
https://www.bridgebio.comBridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $120.7M ▲ | $259.34M ▲ | $-182.74M ▼ | -151.4% ▲ | $-0.96 ▼ | $-173.34M ▼ |
| Q2-2025 | $110.56M ▼ | $241.19M ▲ | $-181.9M ▼ | -164.52% ▼ | $-0.95 ▼ | $-142.7M ▼ |
| Q1-2025 | $116.63M ▲ | $218.37M ▼ | $-167.42M ▲ | -143.55% ▲ | $-0.88 ▲ | $-126.18M ▲ |
| Q4-2024 | $5.88M ▲ | $229.82M ▲ | $-265.05M ▼ | -4.51K% ▲ | $-1.4 ▼ | $-235.05M ▼ |
| Q3-2024 | $2.73M | $193.88M | $-162.04M | -5.93K% | $-0.86 | $-139.66M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $645.94M ▼ | $998.25M ▼ | $2.92B ▲ | $-1.93B ▼ |
| Q2-2025 | $757.34M ▲ | $1.08B ▲ | $2.86B ▲ | $-1.79B ▼ |
| Q1-2025 | $540.6M ▼ | $881.64M ▼ | $2.52B ▲ | $-1.65B ▼ |
| Q4-2024 | $681.1M ▲ | $919.34M ▲ | $2.38B ▲ | $-1.47B ▼ |
| Q3-2024 | $266.32M | $664.98M | $1.88B | $-1.23B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-182.74M ▲ | $-109.57M ▼ | $4.46M ▲ | $-894K ▼ | $-106.33M ▼ | $-110.04M ▼ |
| Q2-2025 | $-183.76M ▼ | $-80.68M ▲ | $-13M ▼ | $302.04M ▲ | $208.36M ▲ | $-85.78M ▲ |
| Q1-2025 | $-169.61M ▲ | $-199.24M ▼ | $-1.59M ▲ | $60.33M ▼ | $-140.5M ▼ | $-200.83M ▼ |
| Q4-2024 | $-267.39M ▼ | $-195.33M ▼ | $-3.24M ▼ | $473.93M ▲ | $275.37M ▲ | $-198.56M ▼ |
| Q3-2024 | $-164.25M | $-180.57M | $38.23M | $707K | $-141.63M | $-182.3M |
Revenue by Products
| Product | Q1-2023 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License and Service | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 Net Product Revenue | $0 ▲ | $40.00M ▲ | $70.00M ▲ | $0 ▼ |
 Product | $0 ▲ | $0 ▲ | $0 ▲ | $110.00M ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Neil Kumar
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 175
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 15
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:16.83M
Value:$1.31B
VIKING GLOBAL INVESTORS LP
Shares:15.98M
Value:$1.24B
BLACKROCK, INC.
Shares:14.41M
Value:$1.12B
Summary
Showing Top 3 of 442